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Abstract
Background: SLC10A1 gene codes NTCP, a receptor through which the hepatitis B virus (HBV) gets access into
hepatocytes - a stage of the viral cycle necessary for replication. Polymorphism variants of SLC10A1 play roles in
HBV infection, viral clearance, treatment outcome, and complications, in diverse ethnic groups and countries.
However, no such study has been conducted in the Ghanaian population, a country with HBV endemicity.
Therefore, an exploratory study was conducted to investigate the presence of three (3) single nucleotide
polymorphisms (SNPs) in the SLC10A1 gene (rs2296651, rs61745930, and rs4646287) and assessed the risk of HBV
infection among the Ghanaian population.
Method: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to
determine the presence of the SNPs among 292 participants comprising 146 HBV infected persons as case-subjects
and 146 HBV non-infected persons as control-subjects.
Results: The minor allele frequency (T) of rs2296651 was present in a significantly high proportion of cases
compared with the control group (11.6% vs. 3.1%, p < 0.0001). The homozygote recessive variant of rs61745930 was
present in 2.7% of the control group and 5.5% of the case group. Moreover, the minor allele frequencies of
rs4646287 were 9.3 and 8.2% among the control and the case group, respectively (p = 0.767). Under the dominant
(CC) genetic model of inheritance, rs2296651 was found to be protective of HBV infection [OR = 0.18 (0.07–0.44)],
whereas under the co-dominant and additive model, rs2296651 was a potential risk factor for HBV infection [OR =
5.2 (95%CI: 2.1–12.8); 3.5 (95%CI: 1.6–7.6], respectively. Variants of rs61745930 and rs4646287 were not associated
with HBV infection (p > 0.05). Polymorphisms in SLC10A1, however, did not show any significant association with
HBV infectivity (p > 0.05).
Conclusion: The study highlights some polymorphism proof that variants rs2296651, rs61745930, and rs4646287
exist in HBV-infected individuals in Ghana. Although variant rs2296651 was found to be associated with HBV
infection, this association warrants more studies. Polymorphisms in SLC10A1 were not associated with HBV
infectivity among the Ghanaian population. Further investigation is warranted to assess the offensive role of the
relationship between rs2296651 and HBV infectivity.
Keywords: SLC10A1, NTCP, SNP, CHB infection, PCR-RFLP
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Introduction
The prevalence of hepatitis B virus (HBV) infection in
regions of high endemicity ranges from 6 to 8%; in
Africa, prevalence rates of 10–15% have been reported
[1, 2]. Within the adult population in Ghana, prevalence
rates between 10 and 13% have been recorded across the
ten regions with a national average rate of 12.3% [3],
which is about 50% higher than the current global average. This predisposes at least 1/10th of every Ghanaian
adult to the risk of later suffering or even dying from
HBV- associated complications such as cirrhosis or
Hepatocellular carcinoma (HCC) [4, 5]. HBV infection,
progression, and complications are affected by factors
such as genes, race, gender, age, and expression of some
biomolecules such as CD4+ T-helper cells [6]. Spontaneous clearance of HBV infection is associated with vigorous polyclonal and multi-specific CD4+T-helper cell
response, compared to the weak responses observed in
persistent or chronic infections [7]. Solute carrier family
10 A1 (SLC10A1) gene-coded Na+-taurocholate cotransporting polypeptide (NTCP) is another molecule
that influences the outcome of HBV infection. It is a
protein receptor through which the HBV gets access
into the hepatocytes, a stage of the viral cycle necessary
for replication [8, 9]. Thus, NTCP could represent a molecular and pharmacologic target for treatment and
prevention.
With the high risk of HBV infection and its associated
end-stage liver complications, the lack of a cure for HBV
infection, high treatment cost [10, 11], low long term
benefits and high toxicity associated with interferon, nucleoside and nucleotide therapies; new treatments and
methods targeting different molecules are warranted.
Single nucleotide polymorphic (SNP) variants of the
NTCP gene – SLC10A1 such as rs7154439, rs4646287
[4, 12, 13], rs2296651 and rs61745930 [14–16] is associated with HBV persistent infection (chronicity), expression of HBeAg and viral clearance among different
ethnic groups and countries. The polymorphic SNP variants in the Ghanaian population or responsible for any
of the HBV infection status are non-existent. Therefore,
this explorative study was conducted to determine the
presence three (3) SNPs in the SLC10A1 gene
(rs2296651, rs61745930, and rs4646287) and the risk of
HBV infection among the Ghanaian population.
Methods
Study design and participant selection

This was a case-control study. Two hundred and ninetytwo (292) participants comprising 146 HBV infected persons as cases (excluding active hepatitis B cases) and 146
apparent healthy HBV non-infected persons as controls
were recruited from the Greater Accra Region of Ghana
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All the participants selected were Ghanaians by birth between 18 and 65 years of age.
Sample size justification

The sample size for the study was calculated using the
Cochran–Armitage trend tests [17]. By considering the
additive genetic model at a case: control ratios of 1:1,
the rare allele frequency (0.079) of the most replicated
SNP (rs2296651), and a national HBV average prevalence of 12.3% [3], the sample size needed to achieve the
prespecified 0.05 α-level and a power 80 for a two-sided
trend test was 348 (174 cases vs 174 controls). The total
response rate of the participants was approximately
84.0% (292/348). The final population of the study constituted 292 participants comprising of 146 cases and
146 controls.
Sample collection, preparation, biochemical analysis, and
DNA isolation

Nine (9) millilitres of venous blood was drawn from each
participant into a 3 ml serum separator gel tube (SST) and
two 3 ml EDTA tubes; thus, one for haematology and the
other for DNA extraction. This was done to avoid contamination. The SST sample was allowed to clot and centrifuged at 2500 g for 7mins to obtain serum and
preserved between − 16 to − 20 °C till assayed. Mindray 5parts hematology analyzer (Mindray, Shenzhen-China,
2013) was used to quantify blood hemoglobin, blood cells
and other cellular indices one EDTA sample, using the
impedance, flow cytometry, and vis -spectrophotometry
methods depending on the analyte or index (Mindray,
2013, 2018). HumaStar 200 Clinical chemistry analyzer
(Human Diagnostics worldwide, Germany, 2014) was used
to quantify the concentrations of total and direct bilirubin,
total protein, albumin; and the activity of the enzymes:
alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (ϒGT) and alkaline phosphatase (ALP) (Human Diagnostics worldwide,
Germany, 2014, 2018). Genomic (g) DNA was isolated
from the other EDTA anticoagulated sample as described
by Suguna, et al. [18], and preserved below − 80 °C until
genotyped.
Profiling of HBV antigens and HBV -host antibodies

The commercial Clinogen HBV-5 card was used to
screen for the presence of two (2) HBV viral antigens
and three (3) host antibodies using colloidal gold and
membrane chromatography technology (Clinogen Diagnostics, Japan) after ‘running’ HBV profile on ELISAconfirmed controls previously obtained from the Noguchi Memorial Institute for Medical Research (NMIMR),
Legon, Accra. HBsAg, HBeAg, and HBsAb were
screened for with the Immunochromatographic (dualantibody sandwich) principle, and the HBeAb and
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HBcAb were screened for by the neutralization competitive inhibition principle (Clinogen Diagnostics, Japan;
Clinogen Diagnostics, UK).
Primer design

Primers spanning each of the SNP variants (rs2296651,
rs61745930, and rs4646287) were designed using the
NCBI Primer-BLAST software and the results shown in
Table S1 (https://www.ncbi.nlm.nih.gov/tools/primerblast/index.cgi). Table S1 shows PCR primers and their
characteristics restriction enzymes.
Genotyping
PCR conditions

To detect the presence of the rs2296651 (about 200 bp,
80), rs61745930 (about 400 bp, 250 bp), and rs4646287
(about 140 bp, 250) fragments, a 25 μL PCR reaction volume consisting of 8.5 μL nuclease-free water, 1 μL
(10 μM) each of forward and reverse primers, 12.5 μL of
One Taq 2x PCR Master mix (New England BioLabs
(NEB), USA) and 2 μL of the isolated genomic DNA was
prepared. Nuclease free water was used in place of the
gDNA in the negative control. PCR amplification was
done using the Applied Biosystems thermal cycler
(Fisher Scientific, USA). Denaturation was completed at
940 C for 3 mins (initial) and 940 C for 30 s (on rest).
Annealing conditions for rs2296651, rs61745930 and
rs4646287 were 580 C (30 s), 59.50 C (35 s) and 60.00 C
(30 s), respectively. Initial and final extension were completed at 720 C (30 s) and 720 C (10 mins), respectively.
The denaturation, annealing and extension steps were
done for 35 cycles, and the hold after the final extension
was at 4 °C.
Restriction digestion

The optimal enzyme concentration was prepared with
the appropriate assay buffer containing 1 μg of substrate
DNA according to Manufacturer’s instructions. Controls
were included to ensure there was no contamination or
unspecific product obtained. To complete the genotyping of rs2296651, 15 μL of the PCR product was added
to 0.2 μL of HphI enzyme (NEB, USA) and dissolved in
1.5 μL of NEB buffer and 3.3 μL of nuclease-free water,
and incubated at 37 0 C for 11 min for the enzyme digestion of the PCR product. Similarly, 15 μL of the PCR
product was either added to 0.2 μL of BsaBI or 0.2 μL of
Taq I enzymes (NEB, USA) and dissolved in 1.5 μL of
NEB buffer and 3.3 μL of nuclease-free water and incubated at 60 0 C for 60 min (1 h) for the enzyme digestion
of either rs61745930 or rs4646287.
Product visualization

The digested fragments were separated with a 2.5%
EtBr- incorporated agarose gel at 100 V, 2A for 90 min,
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and using the Quick-Load purple 100 bp DNA Ladder
(NEB, USA) as the molecular marker (MM) and visualized
under UV trans-illuminator. The genotypes were determined according to the band patterns/sizes and in comparison, to the molecular marker (MM) as shown in the
supplementary figures. Figure S1, Figure S2 and Figure S3
show the gel bands for the SNP rs2296651, rs61745930,
and rs4646287, respectively.
Statistical analysis

Results obtained were entered into the Statistical Package for the Social Sciences (SPSS), coded, and analyzed
using this SPSS (version 23.0). Frequencies were used to
represent categorical data and compared using ChiSquare test analysis to compare the genotype and allele
frequencies between the groups. Skewed data were compared using the Man-Whitney Test. Normally distributed data were represented with mean ± standard
deviation and compared between groups using the Ttest. To test for associations between HBV and every
single SNP, logistic regression models were fitted, in
which each SNP was presented as a predictor variable
whose values were equal to the number of copies of the
minor allele (0, 1, 2) in an additive model, or presence of
at least one copy of the minor allele (0, 1) in a dominant
model or presence of two copies of the minor allele (0,
1) in a recessive model. Sex, age and family history of
HBV status were included as covariates in the fitted
model. The structure of the model was represented as:
Logit [pr(D = 1)] = α + β 1 G.
Where D denotes HBV phenotype; G denotes SNP
coded as an additive, dominant or recessive; β denotes
the corresponding coefficient for each variable in the
model, and its exponential is the corresponding odds ratio. A P-value of less than 0.05 was considered statistically significant.

Results
Table 1 shows the comparison of age, gender, biochemical indices between cases and controls. The male and
female participants were equivalently distributed among
cases and controls (p = 0.193). Total protein, direct
bilirubin, ALT, ALP and de-Ritis ratio did not show any
significant differences between cases and control participants (p > 0.05). However, total bilirubin (p = 0.002), indirect bilirubin (p < 0.0001), and AST (p = 0.007) were
significantly higher in cases compared with controls. On
the other hand, albumin (p = 0.010) and GGT (p = 0.042)
were significantly higher in controls compared with
cases. The aspartate aminotransferase-to-platelet ratio
index (APRI index) (p = 0.003), fibrosis index based on
four factors (FIB-4) (p = 0.009) and RDW-to-platelet ratio (RPR) (p < 0.0001) were significantly higher in the
case-subjects compared to control subjects. Table S2
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Table 1 Descriptive summary of demographic and liver function indices of the study participants
Variables

Control
n = 146

Cases
n = 146

Gender a

P-value
0.193

Male

68 (46.6)

57 (39.0)

Female

78 (53.4)

89 (61.0)

Age (years)

31.3 ± 10.0

30.6 ± 8.1

0.542

Total Bilirubin (μmol/L)

12.73 ± 5.29

14.89 ± 6.56

0.002

Direct Bilirubin (μmol/L)

6.59 ± 3.54

6.44 ± 3.22

0.700

Indirect Bilirubin (μmol/L)

6.08 ± 3.27

8.13 ± 4.50

< 0.0001

Total protein (g/L)

72.35 ± 7.52

70.83 ± 9.97

0.141

Albumin (g/L)

41.69 ± 5.53

39.72 ± 7.35

0.010

ALT (U/L

26.42 ± 11.79

27.33 ± 13.59

0.540

AST (U/L)

27.14 ± 13.30

30.35 ± 19.10

0.007

GGT (U/L)

33.37 ± 16.99

27.72 ± 12.73

0.042

ALP (U/L)

159.7 ± 55.8

159.0 ± 53.

0.914

De Ritis ratio

1.0 (0.80–1.26)

1.03 (0.76–1.47)

0.631

APRI index

0.30 (0.20–0.43)

0.37 (0.25–0.50)

0.003

FIB-4

0.68 (0.49–1.05)

0.80 (0.60–1.18)

0.009

RPR

0.06 (0.04–0.07)

0.07 (0.06–0.10)

< 0.0001

Data is presented as means ± standard deviation. Variables with the superscript “a” were presented as frequency and subgroup proportions. ALT Alanine
aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, APRI index Aspartate aminotransferase-to-platelet ratio index, FIB-4 fibrosis
index based on four factors, RPR RDW-to-platelet ratio, P < 0.05 is considered statistically significant

shows the measured hematological parameters among
cases and control subjects. Apart from RBC count,
MCV, PCT, and hematocrit level (p > 0.05), cases and
control participants significantly differed in terms of
measured hematological parameters.
The genotype and allele frequencies of SLC10A1 gene
polymorphism were compared between cases and control participants (Table 2). The minor allele frequency
(T) of rs2296651 was presenting in a significantly high
proportion of cases compared with the control group
(0.116 vs 0.031, p < 0.0001). Also, the heterozygote
(18.5% vs 6.2%, p = 0.001) and homozygote recessive
(3.4% vs 0%, p = 0.025) variants of rs2296651 were
present in significantly higher proportions of the case
group than the control group, respectively. The homozygote recessive variant of rs61745930 was present in 2.7%
of the control group and 5.5% of the case group. Moreover, the minor allele frequencies of rs4646287 were 9.3
and 8.2% among the control and the case group, respectively (p = 0.767) (Table 2).
Table S3 shows the re-categorised into HBeAg positive
(active) and HBeAg negative (inactive) based on HBV
antigen/antibody profiling. The results indicated that
39.0% were active CHB cases whereas 61.0% were inactive CHB cases.
The genotype and allele frequencies of SLC10A1 gene
polymorphism in active CHB and inactive CHB cases
are shown in Table 3. There were no significant

differences in allele and genotype frequencies among
HBeAg positive and HBeAg negative cases (p > 0.05)
Table 3.
The association between SLC10A1 variants and HBV
infection was compared under the recessive, dominant,
co-dominant and additive model of inheritance. Under
the dominant model, rs2296651 was found to be protective of HBV infection, whereas, under the co-dominant
and additive model, rs2296651 was a risk factor for HBV
infection (Table 4). Polymorphisms in rs61745930 and
rs4646287 were not significantly associated with HBV
infection under any of the models (Table 4).

Discussion
Several studies have reported the presence of SLC10A1
rs2296651, rs61745930, and rs4646287 SNP variants
among persons with HBV infection (4, 14, 24). Thus, we
determined the association between 3 SNPs in the
SLC10A1 gene (rs2296651, rs61745930, and rs4646287)
and the risk of HBV infection among the Ghanaian
population. Our results indicated that the MAF of
rs2296651 was 3.1% among HBV uninfected population
and 11.6% among HBV infected population. These findings are similar to those reported among Korean (3.1%)
and Chinese-Americans (7.5%) populations [14]. Also,
similar findings have been replicated among Chinese
and Vietnamese in a study by Wang, et al. [13]. Moreover, Li, et al. [15] reported a 4.4% MAF of rs2296651
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Table 2 Genotype, allele frequencies of SLC10A1 gene polymorphism in the study participants
SNP

Controls (n = 146)
n (%)

rs2296651

†

P-value

Cases (n = 146)
Allele frequency

n (%)

Allele frequency

C

T

C

T

0.969

0.031

0.884

0.116

< 0.0001

CC

137 (93.8)

114 (78.1)

0.0001

CT

9 (6.2)

27 (18.5)

0.001

TT

a

0

5 (3.4)

0.025

HWE-P‡

1.00

0.112

rs61745930

0.014

0.986

0.028

0.972

142 (97.3)

CT

0

0

–

CC

4 (2.7)

8 (5.5)

0.228

HWE-P‡

0.003

rs4646287

138 (94.5)

0.238

TT

0.228

0.009
0.907

0.093

0.888
0.918

0.082

0.767

CC

120 (82.2)

123 (84.2)

0.648

CT

24 (16.4)

21 (14.4)

0.636

TT

2 (1.4)

2 (1.4)

1.00

HWE-P‡

0.763

0.549

Cases: HBV seropositive, Controls: HBV seronegative, HWE-P Hardy-Weinberg equation p-values, †P-values represents the chi-square test to compare genotype
frequency between case-and control -subjects. P-values for chi-squared test for variant allelic frequency based on HWE, p < 0.05 depicts it not consistent
with HWE

Table 3 Genotype, allele frequencies of SLC10A1 gene polymorphism in active and inactive cases
SNP

Inactive CHB cases (n = 89)

Active CHB cases (n = 57)

N (%)

N (%)

Allele frequency
C

rs2296651

0.882

T

CC

72 (80.9)

CT

13 (14.6)

14 (24.6)

TT

4 (4.5)

1 (1.8)

HWE-P‡

0.123

rs61745930

0.140

0.240

0.035

0.965

0.382

0.088

0.374

0.112
0.956

TT

85 (95.5)

53 (93.0)

CT

0

0

CC

4 (4.5)

4 (7.0)
0.013

rs4646287

T

0.860
42 (73.7)

0.044

HWE-P‡

P-value

Allele frequency
C

0.118

†

0.916

0.009
0.084

0.912

CC

76 (85.4)

47 (82.5)

CT

11 (12.4)

10 (17.5)

TT

2 (2.2)

0

HWE-P‡

0.615

0.821

HWE-P Hardy-Weinberg equation p-values, †P-values represents the chi-square test to compare genotype frequency between case-and control -subjects. P-values
for chi-squared test for variant allelic frequency based on HWE, p < 0.05 depicts it not consistent with HWE
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Table 4 Odds ratios and P-values of SLC10A1 gene polymorphism under recessive, dominant, co-dominant and additive models of
inheritance
Model

Alleles

aOR (95% CI)

bOR (95% CI)

mt/wt CT + wt/wt TT

1 (reference)

1 (reference)

mt/mt CC

n/a

2.70 (0.29–24.78)

mt/wt TC + mt/mt TT

1 (reference)

1 (reference)

wt/wt CC

0.18 (0.07–0.44) *

1.55 (0.70–3.43)

wt/wt CC + mt/mt TT

1 (reference)

1 (reference)

mt/wt TC

5.2 (2.1–12.8) *

0.85 (0.4–1.6)

mt/wt TC

1 (reference)

1 (reference)

mt/mt TT

5.23 (2.09–13.11) *

0.49 (0.20–1.16)

rs2296651
Recessive Model

Dominant Model

Co-dominant model

Additive model 1

rs61745930
Additive Model

wt/wt TT

1 (reference)

1 (reference)

mt/mt CC

1.5 (0.7–3.2)

0.80 (0.4–1.6)

mt/wt TC + wt/wt TT

1 (reference)

1 (reference)

mt/mt TT

n/a

n/a

mt/wt TC + mt/mt TT

1 (reference)

1 (reference)

wt/wt CC

0.81 (0.35–1.85)

1.31 (0.53–3.24)

wt/wt CC + mt/mt TT

1 (reference)

1 (reference)

mt/wt CT

1.10 (0.50–2.4)

0.96 (0.4–2.2)

mt/wt TC

1 (reference)

1 (reference)

mt/mt TT

1.34 (0.58–3.10)

0.65 (0.25–1.66)

rs4646287
Recessive

Model

Dominant Model

Co-dominant model

Additive model 1

mt mutant type, wt wild type, Highlighted values represent statistically significant values. CI-confidence interval; “*” represent statistically significant model, p f <
0.05. aOR- odds ratios for controls vs cases; bOR- odds ratios HBeAg positive and HBeAg negative

among the Chinese Han population. In a more recent
study among Vietnamese, the rs2296651 variant was reported in an average of 6% of the population, with a T
minor allele frequency of 3% [19].
Also, the distribution of the MAF of rs61745930 and
rs4646287 were 1.4 and 9.3% among HBV uninfected
population, and 2.8 and 8.2% among HBV infected
population. Variants of rs4646287 had the highest frequency among the study participants, with about 16.4
and 1.4% of the Ghanaian HBV uninfected population
carrying the codominant (CT) and recessive (TT) variants, respectively. Lower frequencies of the variant than
these were observed among the Chinese Han [20] and
Chinese [21] population. Also, Chuaypen, et al. [22] reported rs4646287 average MAF of 17.3% among the Thai
population with CT and TT genotype frequencies of 16
and 1.3% respectively and the T minor allele was found to
be 9.3%. These findings indicate that the rs2296651,
rs61745930, and rs4646287 SLC10A1 polymorphisms -its
genotypes and alleles- are widely distributed among Asians
and the Ghanaian population. However, some studies have
reported the absence or low prevalence of these SLC10A1
SNP variants in Caucasians [23]. Thus, replication studies
among a wider population of Ghanaians and the entire of

Africa are warranted since these countries represent HBV
endemic territories.
We observed that variants of rs2296651 were associated with the risk of HBV infection. However, the association was independent of HBV infectivity. Under the
recessive, additive and codominant model of inheritance,
we observed that rs2296651 was associated with the increased risk of HBV infection. On the other hand, under
the dominant genetic inheritance model, we observed
that rs2296651 was protective of HBV infection. Several
studies have indicated that variants of rs2296651 either
increases an individual’s susceptibility to HBV infection
and/or its complications, makes resolution/viral clearance of the infection faster or improves the prognostic
outcome of cirrhosis and HCC [15, 19–22]. The evidence of the transferability of rs2296651 associated with
HBV infection has been demonstrated among the Han
population [15], Taiwanese [24] and Vietnamese [19].
However, unlike our results, rs2296651 [(c.800C > T)
(S267F)] has been associated with reduced HBV infection and associated hepatic complications [25]. Among
the population of Thailand, the rs2296651 SNP variant
was associated with inactive and non-infectious CHB
and viral clearance among HBV infected persons [22].
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These findings indicate that although variants of
rs2296651 are associated with HBV infection, the definition of the risk variant may be dependent on the genetic
architecture of the population as well as the environmental agents identified as risk factors for HBV
infection.
The study has some limitations that should be acknowledged. The sample of the study was small which
may affect power replication of the odds of NTCP polymorphic variants associated with HBV infection. Also,
the study was localized, and generalization of findings
should be done with caution, and therefore recommend
replication studies in other parts of the country considering the limitation of this study. Although further studies are required, we have demonstrated the feasibility of
the association of rs2296651 with HBV infection in the
Ghanaian population and our findings are congruent
with previous reports among the Asian populations.

Conclusion
The study highlights some polymorphism proof that variants of rs2296651, rs61745930, and rs4646287 exist in
HBV-infected individuals in Ghana. Although, variant
rs2296651 was found to be associated with HBV infection. Polymorphisms in SLC10A1 is not associated with
HBV infectivity among the Ghanaian population. Further investigation is warranted to assess the predisposition role of the relationship between rs2296651 and
HBV infectivity.
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